Global CAR-T Therapy Market Report 2021 - Opportunities And Strategies, Market Forecast And Trends
5 Mar, 2021
The chimeric antigen receptor -T therapy market consists of sales of CAR-T therapy products and related services by entities (organizations, sole traders and partnerships) that develop chimeric antigen receptor (CAR) T-cell therapies to treat blood cancers. CAR-T therapy is type of immunotherapy in which T-cells taken from patient’s blood are modified in a laboratory with the addition of a special protein receptor that grants T-cells the power to recognize as well as kill cancer cells easily, along with infusing the same back into that patient. This special protein receptor, known as chimeric antigen receptor (CAR), attaches to a specific protein on a patient’s cancer cells. The infused cells multiply and prevail in the patient’s body as living drugs.
Global CAR-T Therapy Market Size And Drivers:
The global CAR-T therapy market reached a value of nearly $734.0 million in 2019. The market is expected to grow from $734.0 million in 2019 to $2.25 billion in 2023 at a rate of 32.3%. The market is expected to stabilize and reach $3.15 billion in 2025 and $6.10 billion in 2030. The rise in the blood cancer incidence rate globally is anticipated to boost the demand for the CAR-T therapy market over the forthcoming years.
Request For A Sample For The Global CAR-T Therapy Market Report:
Trends In The Global CAR-T Therapy Market
The developers and providers of the CAR-T therapy market are investing in research and development to remodel the design of CAR-T therapy to reduce its side effects on cancer patients. The original CAR-T therapy causes neurologic side effects such as delirium, speech problems, seizures and tremors though it provides long-lasting remissions for some patients with very advanced cancer. The remodeled CAR-T therapy with a renewed design results in far fewer neurologic side effects than that of the original therapy. It also helps to reduce the levels of cytokines which cause neurologic side effects.
Global CAR-T Therapy Market Segments:
The global chimeric antigen receptor-T therapy market is further segmented based on target antigen, application and geography.
By Target Antigen:CD19 Therapy, CD22 Therapy, BCMA Therapy, Others
By Application: Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma, Others.
By Geography:The global chimeric antigen receptor-T therapy market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa.
Among these regions, North America is the largest region in the global chimeric antigen receptor-T therapy market, accounting to 60.3% of total market.
Read More On The Report For The Global CAR-T Therapy Market At:https://www.thebusinessresearchcompany.com/report/car-t-therapy-market
CAR-T Therapy Global Market Report 2021 is one of a series of new reports from The Business Research Company that provides chimeric antigen receptor-T therapy market overviews, analyzes and forecasts market size and growth for the global chimeric antigen receptor-T therapy market, chimeric antigen receptor-T therapy market share, chimeric antigen receptor-T therapy market players, chimeric antigen receptor-T therapy market segments and geographies, chimeric antigen receptor-T therapy market’s leading competitors’ revenues, profiles and market shares. The chimeric antigen receptor-T therapy market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.